Nexus Select Trust REIT Fund Raise of ₹100 Cr

Nexus Select Trust REIT Other Announcement

Nexus Select Trust filed its Security Cover Certificate as per Regulation 54 of SEBI (LODR) Regulations, 2015, for the quarter ended June 30, 2026.

Nexus Select Trust REIT Results Update

Nexus Select Trust reported Q1 FY27 results with NOI of ₹510 Crore and a distribution of ₹370 Crore, highlighting portfolio growth and operational performance.

Nexus Select Trust REIT Q1 FY27 Results: Net Profit ₹156.5 Cr, Up 30.9% YoY

Nexus Select Trust REIT reported revenue from operations of ₹680.5 Cr (+10.9% YoY) and net profit of ₹156.5 Cr (+30.9% YoY) for Q1 FY27.

Key figure

Net profit ₹156.5 Cr · +30.9% YoY

Nexus Select Trust REIT Credit Rating

Nexus Select Trust received reaffirmed 'Crisil AAA/Stable' and 'Crisil A1+' credit ratings from Crisil Ratings for its commercial papers and non-convertible debentures.

Nexus Select Trust REIT Annual General Meeting

Nexus Select Trust held its Fourth Annual Meeting on July 29, 2026. Unitholders considered the adoption of FY26 financial statements and the appointment of new service providers.

Nexus Select Trust REIT Board Meeting Date

Nexus Select Trust will hold a Board Meeting on August 03, 2026, to consider financial results and distributions to unitholders for the quarter ended June 30, 2026.

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr